Mark Zuckerberg and his wife, Priscilla Chan, are shifting their philanthropy's focus to science and AI (www.businessinsider.com)

Mark Zuckerberg and Priscilla Chan are refocusing their philanthropy around AI-driven biology, directing the Chan Zuckerberg Initiative’s major bets toward Biohub — a research network they’ve supported since 2016 — and announcing a partnership with AI infrastructure firm EvolutionaryScale. The move formalizes a broader pivot away from earlier education and policy priorities and signals a major infusion of private philanthropic capital into applied life‑science research. Zuckerberg framed the shift as a way to compress decades of discovery into months, arguing advances in AI make cures and prevention far more attainable. Technically, Biohub laid out four scientific challenges it will tackle, notably using AI to reprogram and harness the immune system for earlier detection, prevention and treatment of disease, and plans to scale compute to 10,000 GPUs by 2028 to support large models and high‑throughput biology. For AI/ML researchers this means new datasets, compute resources and translational targets (immunology, diagnostics, therapeutics), plus opportunities and tensions around access, reproducibility and governance as a wealthy private actor accelerates proprietary bio‑AI work. If successful, the effort could materially speed drug discovery and systems‑level biology, but it also raises questions about openness, oversight and how philanthropic influence shapes research priorities.